Original articleClinical endoscopyOpen-label, sham-controlled trial of an endoscopic duodenojejunal bypass liner for preoperative weight loss in bariatric surgery candidates
Section snippets
Mechanisms of weight loss
RYGB and BPD reroute chyme such that the duodenum and proximal jejunum are bypassed, promoting chyme delivery directly to the jejunum.5 In an effort to treat obese patients less invasively, nonsurgical endoluminal procedures have been attempted with variable success.13, 14 Many share the ability to reduce gastric volume, thereby restricting the passage of food through the stomach into the duodenum. An alternative approach would be to duplicate the effects of the gastric bypass/BPD by diverting
Study population
This 12-week, open-label, randomized trial investigated the use of the DJBL versus a sham upper endoscopy for weight loss before bariatric surgery. It was conducted from May 2007 to November 2008 at 4 sites in the United States in accordance with Good Clinical Practice and in compliance with each institution's Investigational Review Board.
Subjects were people 18 years of age or older and 55 years of age or younger in whom nonsurgical weight loss treatments failed. The baseline BMI was 40 kg/m2
Study population
Sixty-nine subjects were screened, with 58 meeting all inclusion and no exclusion criteria (Fig. 3). Two subjects withdrew before randomization at their request. Twenty-seven subjects were randomized to the DJBL arm and 29 to the sham arm. Two subjects initially randomized to the DJBL arm were removed before implantation at their request. In the sham arm, 2 subjects were discontinued at their request, and a third was lost to follow-up. Therefore, 25 subjects randomized to the DJBL arm underwent
Discussion
This 12-week trial evaluated the safety and weight loss efficacy of the DJBL as adjunctive therapy before bariatric surgery. Subjects who tolerated the DJBL experienced significantly greater weight loss than sham subjects, even though both groups received the same preoperative nutritional counseling.
There is a growing acceptance among clinicians that preoperative weight loss is beneficial for those undergoing bariatric surgery.9, 10, 11, 12, 18, 19, 20 The 1998 National Institutes of Health
Conclusions
The DJBL can be safely implanted and explanted endoscopically and maintained for 12 weeks. Importantly, the DJBL achieved significant preoperative weight loss compared with standard counseling in candidates for bariatric surgery. These data support further clinical research with the DJBL in obese subjects.
Acknowledgments
The authors thank Andy Levine, Ken Malomo, and Aurora Liao, PhD, for data analysis and assistance in the conduct of the study, and Loretta L. Nielsen, PhD, for medical writing.
References (23)
- et al.
First human experience with endoscopically delivered and retrieved duodenal-jejunal bypass sleeve
Surg Obes Relat Dis
(2008) - et al.
Is there a benefit to preoperative weight loss in gastric bypass patients?A prospective randomized trial
Surg Obes Relat Dis
(2007) - et al.
Benefits of patients choosing preoperative weight loss in gastric bypass surgery: new results of a randomized trial
J Am Coll Surg
(2009) - et al.
Effect of stent size on complications and recurrent dysphagia in patients with esophageal or gastric cardia cancer
Gastrointest Endosc
(2007) - et al.
Prevalence of overweight and obesity in the United States, 1999-2004
JAMA
(2006) - et al.
Impact of overweight on the risk of developing common chronic diseases during a 10-year period
Arch Intern Med
(2001) Prospective Studies Collaboration: Body-mass index and cause-specific mortality in 900,000 adults: collaborative analyses of 57 prospective studies
Lancet
(2009)- et al.
Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001
JAMA
(2003) - et al.
Bariatric surgery: a systematic review and meta-analysis
JAMA
(2004) - et al.
Surgical treatment of obesity
Eur J Endocrinol
(2008)
Why patients seek bariatric surgery: a qualitative and quantitative analysis of patient motivation
Obes Surg
Cited by (0)
DISCLOSURE: The following author disclosed financial relationships relevant to this publication: K.S. Gersin: Consultant to and shareholder in GI Dynamics. All other authors disclosed no financial relationships relevant to this publication. This work was supported by funding from GI Dynamics, Inc.
See CME section; p. 1028